Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective

References

• Citrome L, Dufresne R, Dyrud JM. Tardive dyskinesia: minimizing risk and improving outcomes in schizophrenia and other disorders. Am J Manag Care. 2007;13(Suppl):1–12.
   Google Scholar
• Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res. 1999;35(Suppl):S61–S66.
   PubMedGoogle Scholar
• Citrome L. Clinical management of tardive dyskinesia: five steps to success. J Neurol Sci. 2017;383:199–204.
   PubMed Web of Science ®Google Scholar
• Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother. 2012;13:1599–1613.
   PubMed Web of Science ®Google Scholar
• ANI Pharmaceuticals. REGLAN (metoclopramide) tablets, for oral use. Prescribing information. [update Aug 2017; cited 2018 Jan 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017854s062lbl.pdf
   Google Scholar
• Carbon M, Hsieh CH, Kane JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78:e264–e278.
   PubMed Web of Science ®Google Scholar
• Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med. 2010;122(4):39–48.
   PubMed Web of Science ®Google Scholar
• Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2015;69:978–997.
   PubMed Web of Science ®Google Scholar
• Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry. 2005;50:541–547.
   PubMed Web of Science ®Google Scholar
• Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry. 2003;160:1117–1124.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less “go” and more “stop” from the motor striatum for robust therapeutic effects. CNS Spectr. 2017 Dec 18:1–6. Epub ahead of print. DOI: 10.1017/S1092852917000621.
   Web of Science ®Google Scholar
• Zai CC, Maes MS, Tiwari AK, et al. Genetics of tardive dyskinesia: promising leads and ways forward. J Neurol Sci. [2018 Feb 5]  Epub ahead of print. DOI: 10.1016/j.jns.2018.02.011.
   Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare; 1976.
   Google Scholar
• Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988;39:1172–1177.
   PubMedGoogle Scholar
• Neurocrine Biosciences. INGREZZA (valbenazine) capsules, for oral use. Prescribing information.[updated 2017 Oct; cited 2018 Jan 26]. Available from: https://ingrezza.com/HCP/PI
   Google Scholar
• Teva Pharmaceuticals. AUSTEDO (deutetrabenazine) tablets, for oral use. Prescribing information. [update 2017 Aug; cited 2018 Jan 26]. Available from: https://www.austedo.com/hd/pi
   Google Scholar
• Citrome L. Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017;71:e12964.
   Web of Science ®Google Scholar
• Citrome L. Deutetrabenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017;71:e13030.
   Web of Science ®Google Scholar
• Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486–487.
   PubMed Web of Science ®Google Scholar
• Mamo DC, Sweet RA, Keshavan MS. Managing antipsychotic-induced parkinsonism. Drug Saf. 1999;20:269–275.
   PubMed Web of Science ®Google Scholar
• Merck. COGENTIN (benztropine mesylate injection). Prescribing information. [update 2013 Apr; cited 2018 Jan 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012015s026lbl.pdf
   Google Scholar
• Bergman H, Soares-Weiser K. Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Jan 17;1:CD000204.
   PubMedGoogle Scholar
• Vinogradov S, Fisher M, Warm H, et al. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009;166:1055–1062.
   PubMed Web of Science ®Google Scholar
• Correll CU, Kane JM, Citrome LL. Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. J Clin Psychiatry. 2017;78:1136–1147.
   PubMed Web of Science ®Google Scholar
• Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry. 2005;50:703–714.
   PubMed Web of Science ®Google Scholar
• Roth LS. Tarvil for tardive dyskinesia: are we robbing Peter to pay Paul? Federal Practitioner. 2004;21(11):48, 53, 56–62.
   Google Scholar
• Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2013;81:463–469.
   PubMed Web of Science ®Google Scholar
• Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147:445–451.
   PubMed Web of Science ®Google Scholar
• Zheng W, Xiang YQ, Ng CH, et al. Extract of ginkgo biloba for tardive dyskinesia: meta-analysis of randomized controlled trials. Pharmacopsychiatry. 2016;49:107–111.
   PubMed Web of Science ®Google Scholar
• Pappa S, Tsouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33:271–275.
   PubMed Web of Science ®Google Scholar
• Angus S, Sugars J, Boltezar R, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997;17:88–91.
   PubMed Web of Science ®Google Scholar
• Endo Pharmaceuticals. SYMMETREL (Amantadine Hydrochloride, USP) tablets and syrup prescribing information. [update 2009 Jan; cited 2018 Jan 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016023s041,018101s016lbl.pdf
   Google Scholar
• Adamas Pharma. GOCOVRI (amantadine) extended release capsules, for oral use. Prescribing information. [update 2017 Aug; cited 2018 Jan 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208944lbl.pdf
   Google Scholar
• Lundbeck. XENAZINE (tetrabenazine) tablets, for oral use. Prescribing information. [update Jun 2015; cited 2018 Jan 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021894s010lbl.pdf
   Google Scholar
• Meyer JM. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectr. 2016;21(S1):13–24.
   PubMed Web of Science ®Google Scholar
• Chandler JH. Reserpine in the treatment of Huntington’s chorea. Med Bull (Ann Arbor). 1955;21:95–100.
   PubMedGoogle Scholar
• Erickson JD, Schafer MK, Bonner TI, et al. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci U S A. 1996;93:5166–5171.
   PubMed Web of Science ®Google Scholar
• German CL, Baladi MG, McFadden LM, et al. Regulation of the dopamine and vesicular monoamine transporters: pharmacological targets and implications for disease. Pharmacol Rev. 2015;67:1005–1024.
   PubMed Web of Science ®Google Scholar
• Bernstein AI, Stout KA, Miller GW. The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochem Int. 2014;73:89–97.
   PubMed Web of Science ®Google Scholar
• Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther. 1959;127:103–109.
   PubMed Web of Science ®Google Scholar
• Brandrup E. Tetrabenacine treatment in persisting dyskinesia caused by psychopharmaca. Am J Psychiatry. 1961;118:551–552.
   PubMed Web of Science ®Google Scholar
• Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia, I: clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry. 1972;27:95–99.
   PubMed Web of Science ®Google Scholar
• Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry. 1973;130:479–483.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156:1279–1281.
   PubMed Web of Science ®Google Scholar
• Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010;8:331–373.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Ondo WG, Dashtipour K, et al. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012;34:1487–1504.
   PubMed Web of Science ®Google Scholar
• Prestwick Pharmaceuticals. Briefing document for Peripheral and Central Nervous System Advisory Committee. [2007 Dec 6 and revised 2007 Nov 9; cited 2018 Mar 17]. Available from: https://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4328b1-02-Prestwick.pdf
   Google Scholar
• Grigoriadis DE, Smith E, Hoare SRJ, et al. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017;361:454–461.
   PubMed Web of Science ®Google Scholar
• Skor H, Smith EB, Loewen G, et al. Differences in dihydrotetrabenazine isomer concentrations following administration of tetrabenazine and valbenazine. Drugs R D. 2017;17:449–459.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Factor SA, Marder SR, et al. KINECT 3: A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476–484.
   PubMed Web of Science ®Google Scholar
• Factor SA, Remington G, Comella CL, et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year kinect 3 extension study. J Clin Psychiatry. 2017;78:1344–1350.
   PubMed Web of Science ®Google Scholar
• O’Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015;30:1681–1687.
   PubMed Web of Science ®Google Scholar
• Thai-Cuarto D, O’Brien CF, Jimenez R, et al. Cardiovascular profile of valbenazine: analysis of pooled data from three randomized, double-blind, placebo-controlled trials. Drug Saf. 2017 Dec 7. Epub ahead of print. DOI: 10.1007/s40264-017-0623-1.
   Web of Science ®Google Scholar
• Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88:2003–2010.
   PubMed Web of Science ®Google Scholar
• Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4:595–604.
   PubMed Web of Science ®Google Scholar
• Anderson K, Stamler D, Davis M, et al. Deutetrabenazine for the treatment of tardive dyskinesia: results from an open-label, long-term study. Poster Presentation P7-009. The American Psychiatric Association 2017 Annual Meeting; San Diego, California, 2017 May 20-24.
   Google Scholar
• Anderson K, Stamler D, Davis M, et al. Long-term safety of deutetrabenazine for the treatment of tardive dyskinesia: results from an open-label, long-term study. Mov Disord. 2017;32:S1578.
   Web of Science ®Google Scholar
• Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10:1917–1928.
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. A Look at VMAT2 inhibitors for tardive dyskinesia. [2017 Dec; cited 2018 Feb 1]. Available from: https://icer-review.org/wp-content/uploads/2017/12/icer_tardive-dyskinesia_RAAG-122217.pdf
   Google Scholar